US5283268A - Compounds for the treatment of inflammation and allergy - Google Patents

Compounds for the treatment of inflammation and allergy Download PDF

Info

Publication number
US5283268A
US5283268A US07/846,011 US84601192A US5283268A US 5283268 A US5283268 A US 5283268A US 84601192 A US84601192 A US 84601192A US 5283268 A US5283268 A US 5283268A
Authority
US
United States
Prior art keywords
compound
physiologically acceptable
acceptable salt
solvate
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/846,011
Inventor
Malcolm Johnson
Clifford J. Whelan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Assigned to GLAXO GROUP LIMITED, A BRITISH COMPANY reassignment GLAXO GROUP LIMITED, A BRITISH COMPANY ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: JOHNSON, MALCOLM, WHELAN, CLIFFORD J.
Application granted granted Critical
Publication of US5283268A publication Critical patent/US5283268A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • This invention relates to a new medical use for the dichloroaniline compound 4-amino-3,5-dichloro- ⁇ -[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzenemethanol, physiologically acceptable salts and solvates thereof and pharmaceutical compositions containing them which are disclosed in published UK Patent Specification No. 2187734A, in the treatment of inflammation, allergy, and allergic reaction.
  • Acute inflammation is the result of a number of processes including the activation of inflammatory cells and their accumulation in tissues; the local release of pro-inflammatory and chemotactic mediators; and vascular permeability changes which lead to plasma protein extravasation (PPE) and oedema formation.
  • PPE plasma protein extravasation
  • bronchial asthma is a multifactorial disease characterised by episodic bronchoconstriction, airway hyper-reactivity, inflammation and mucus abnormalities.
  • bronchial asthma has been treated by combination therapy, using selective ⁇ 2 -stimulants such as salbutamol to control bronchospasm and steroidal drugs such as beclomethasone dipropionate to control the inflammatory condition.
  • ⁇ 2 -adrenoreceptor agonists including salbutamol have been reported to exhibit inhibitory effects on inflammatory mediator release (see, for instance, P. R. Butchers et, al., Br. J. Pharmac., 71, 663-667 (1980) and P. H. Howarth et al., Am. Rev Resp.
  • ⁇ 2 -adrenoreceptor agonists are not widely recognised as having significant clinical anti-inflammatory properties.
  • ⁇ 2 -stimulants do not inhibit the so-called late asthmatic response which is classically observed some three to five hours after allergen exposure following recovery from the early asthmatic response. The late asthmatic response is not alleviated by treatment with conventional ⁇ 2 -stimulants.
  • X represents a bond or a C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene chain;
  • Y represents a bond or a C 1-4 alkylene, C 2-4 alkenylene or C 2-4 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is not more than 8;
  • Py represents a pyridinyl group optionally substituted by one or two substituents selected from halogen atoms, or hydroxy, C 1-3 alkyl or C 1-3 alkoxy groups;
  • R 1 and R 2 each represents a hydrogen atom or C 1-3 alkyl group with the proviso that the sum total of carbon atoms in R 1 and R 2 is not more than 4; and physiologically acceptable salts and solvates (e.g. hydrates) thereof.
  • Suitable physiologically acceptable salts of the compounds of general formula (I) include acid addition salts derived from inorganic and organic acids, such as hydrochlorides, hydrobromides, sulphates, phosphates, maleates, tartrates, citrates, benzoates, 4-methoxybenzoates, 2- or 4-hydroxybenzoates, 4-chlorobenzoates, benzenesulphonates, p-toluenesulphonates, methanesulphonates, naphthalenesulphonates, fumarates, succinates, lactates, glutarates, gluconates, tricarballylates, hydroxy-naphthalenecarboxylates e.g. 1-hydroxy-or 3-hydroxy-2-naphthalenecarboxylates, or oleates.
  • acid addition salts derived from inorganic and organic acids such as hydrochlorides, hydrobromides, sulphates, phosphates, maleates, tartrates, citrates,
  • a preferred compound of formula (I) for use according to the present invention is 4-amino-3,5-dichloro- ⁇ -[[[6-[2-(2-pyridinyl) ethoxy]hexyl]amino]methyl]benzenemethanol, hereinafter referred to as "Compound A”, which may be represented by the formula (Ia) ##STR2## and its physiologically acceptable salts and solvates.
  • Compound A is preferably administered in the form of its fumarate salt preferably, its z:1 fumarate salt.
  • the compounds disclosed in the aforementioned patent specification are described as selective ⁇ 2 -adrenoreceptor agonists having a long duration of action which are particularly useful in the treatment of diseases associated with reversible airways obstruction, such as asthma and chronic bronchitis.
  • the compounds of formula (I) exhibit a significant anti-inflammatory activity in vivo over a prolonged period such that the compounds of formula (I) are effective in the treatment of the inflammatory component of bronchial asthma.
  • Compound A or a physiologically acceptable salt or solvate thereof may be used in the treatment of a mammal, including man, suffering from pulmonary inflammation including alveolar inflammation and inflammation of the respiratory airways.
  • Compound A or a physiologically acceptable salt or solvate thereof is useful in the treatment of inflammation associated with pulmonary diseases such as asthma and chronic bronchitis, emphysema, cystic fibrosis and adult respiratory distress syndrome (ARDS).
  • pulmonary diseases such as asthma and chronic bronchitis, emphysema, cystic fibrosis and adult respiratory distress syndrome (ARDS).
  • ARDS adult respiratory distress syndrome
  • Compound A or a physiologically acceptable salt or solvate thereof may also be used in the treatment of a mammal, including man, suffering from pulmonary inflammation associated with the late asthmatic response.
  • Compound A or a physiologically acceptable salt or solvate thereof may be used in the treatment of a mammal, including man, suffering from an allergy or allergic reaction such as allergic rhinitis, contact dermatitis, allergic conjunctivitis and the like or an inflammatory condition such as episcleritis, tendinitis, rheumatoid opondylitis, osteoarthritis, gouty arthritis and other arthritic conditions.
  • an allergy or allergic reaction such as allergic rhinitis, contact dermatitis, allergic conjunctivitis and the like or an inflammatory condition such as episcleritis, tendinitis, rheumatoid opondylitis, osteoarthritis, gouty arthritis and other arthritic conditions.
  • Compound A or a physiologically acceptable salt or solvate thereof is particularly useful in the treatment of inflammatory and allergic skin diseases such as, for example, urticaria, psoriasis, eczema and atopic dermatitis.
  • Compound A or a physiologically acceptable salt or solvate thereof may also be used in the treatment of a mammal, including man, suffering from inflammation of the gastrointestinal tract.
  • Such conditions may be for example, ulcerative colitis, Crohn's disease, damage caused by non-steroidal drugs, and inflammatory bowel disease.
  • a therapeutic agent comprising as active ingredient Compound A or a physiologically acceptable salt or solvate thereof for use in treating, relieving or preventing the effects of inflammation, allergy, or allergic reaction.
  • the invention provides a method of treatment of a mammal, including man, suffering from or susceptible to the effects of inflammation, allergy or allergic reaction which comprises administering an effective amount of Compound A or a physiologically acceptable salt or solvate thereof. It will be appreciated that whilst Compound A will primarily be of use in the alleviation of established symptoms, prophylaxis is not excluded.
  • the invention provides Compound A or a physiologically acceptable salt or solvate thereof for use in the manufacture of a medicament for treating relieving or preventing the effects of inflammation, allergy, or allergic reaction.
  • a particularly preferred compound for use in accordance with the present invention is the (R) enantiomer of Compound A or a physiologically acceptable salt or solvate thereof.
  • the anti-inflammatory activity of Compound A in the lung was assessed by investigating the effect of the drug on inflammatory mediator release in human lung tissues in vitro, and on inflammatory cell infiltration and accumulation, and vascular permeability and plasma protein extravasation in the airway lumen of the guinea-pig in vivo (see Example 1, below).
  • the anti-inflammatory activity of the Compound A in the skin was assessed by investigating the effect of the drug on plasma protein extravasation (PPE) as a measure of vascular permeability (see Example 2, below).
  • PPE plasma protein extravasation
  • the invention provides Compound A or a physiologically acceptable salt or solvate thereof for use in treating, relieving or preventing a disease involving inflammatory cell accumulation in the lungs.
  • the invention provides Compound A or a physiologically acceptable salt or solvate thereof for use in treating, relieving or preventing a disease involving increased vascular permeability and plasma protein extravasation in the lungs.
  • the invention further provides Compound A or a physiologically acceptable salt or solvate thereof for use in treating, relieving or preventing a disease involving granulocyte accumulation in the skin.
  • the invention still further provides Compound A or a physiologically acceptable salt or solvate thereof for use in treating, relieving or preventing a disease involving increased vascular permeability in the skin.
  • the term "increased vascular permeability" is intended to refer to elevated levels of vascular permeability with respect to those generally observed in a healthy individual.
  • FIG. 1 shows a comparison of the inhibition by the (R)-enantiomer of Compound A and salbutamol of leukotriene release from human lung tissue fragments in vitro.
  • FIG. 2 shows the inhibition by the (R)-enantiomer of Compound A of histamine-induced plasma protein extravasation (PPE) in guinea pig lung in vivo.
  • FIG. 3 shows the duration of inhibition by the (R)-enantiomer of Compound A of histamine-induced plasma protein extravasation (PPE) in guinea pig lung in vivo.
  • FIG. 4 shows the duration of inhibition by salbutamol of histamine-induced plasma protein extravasation (PPE) in guinea pig lung in vivo (for comparison with FIG. 3).
  • PPE histamine-induced plasma protein extravasation
  • FIG. 5 shows the inhibition by the (R)-enantiomer of Compound A of bradykinin-induced plasma protein extravasation (PPE) in guinea pig skin.
  • FIG. 6 shows the inhibition by the (S)-enantiomer of Compound A of bradykinin-induced plasma protein extravasation (PPE) in guinea pig skin.
  • Formulations of Compound A for use according to the invention comprise the active compound together with one or more pharmaceutically acceptable carriers and optionally any other therapeutic ingredients.
  • the carriers must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the other therapeutic ingredients may include analgesics, such as aspirin or codeine, anti-pyretics, or other anti-inflammatories.
  • Compound A for use according to the invention may be formulated in a conventional manner for administration by any convenient route, for example for administration by inhalation or insufflation, or for oral, buccal, parenteral, topical (including nasal) or rectal administration.
  • the compound for use according to the invention is conveniently delivered in the form of an aerosol spray presentation from pressurised packs, with the use of a suitable propellants such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas, or from a nebuliser.
  • a suitable propellants such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas, or from a nebuliser.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Compound A may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such a lactose or starch.
  • the powder composition may be presented in unit dosage form in, for example, capsules or cartridges of e.g. gelatin, or blister packs from which the powder may be administered with the aid of an inhaler or insufflator.
  • the pharmaceutical composition may take the form of, for example, tablets, capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.
  • composition may take the form of tablets, drops or lozenges formulated in a conventional a manner.
  • Compound A may be formulated for parenteral administration.
  • Formulations for injections may be presented in unit form in ampoules, or multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and or dispersing agents.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g sterile pyrogen-free water, before use.
  • the pharmaceutical composition may take the form of ointments, lotions or creams formulated in a conventional manner, with for example an aqueous oily base, generally with the addition of suitable thickening agents and or solvents.
  • the composition may take the form of a spray, formulated for example as an aqueous solution or suspension or as an aerosol with the use of a suitable propellant.
  • Compound A may also be formulated in rectal compositions such as suppositories or retention enemas, e.g containing conventional suppository bases such as cocoa butter or other glycerides.
  • compositions are described above for oral, buccal, rectal or topical administration, these may be presented in a conventional manner associated with controlled release forms.
  • a proposed daily dosage of active compound for the treatment of man is 0.0005 mg to 100 mg, which may be conveniently administered in one or two doses.
  • the precise dose employed will of course depend on the age and condition of the patient and on the route of administration.
  • a suitable dose for administration by inhalation is 0.0005 mg to 10 mg
  • for oral administation is 0.02 mg to 100 mg
  • for parenteral administration is 0.001 mg to 2 mg.
  • active ingredient is used herein to represent Compound A.
  • These may be prepared by the normal methods such as wet granulation or direct compression.
  • the active ingredient is sieved through a suitable sieve, blended with the excipients and compressed using 7 mm diameter punches.
  • Tablets of other strengths may be prepared by altering the ratio of active ingredient to microcrystalline cellulose or the compression weight and using punches to suit.
  • the active ingredient is sieved through a suitable sieve and blended with lactose, starch and pregelatinised maize starch. Suitable volumes of purified water are added and the powders are granulated. After drying, the granules are then compressed into tablets using 7 mm diameter punches. Tablets of other strengths may be prepared by altering the ratio of active ingredient to lactose or the compression weight and using punches to suit.
  • Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted, using acid or alkali, to that of optimum stability and/or facilitate solution of the active ingredient.
  • suitable buffer salts may be used.
  • the solution is prepared, clarified and filled into appropriate size ampoules sealed by fusion of the glass.
  • the injection is sterilised by heating in an autoclave using one of the acceptable cycles.
  • the solution may be sterilised by filtration and filled into sterile ampoules under acceptable conditions.
  • the solution may be packed under an inert atmosphere of nitrogen or other suitable gas.
  • the active ingredient is micronised in a fluid energy mill to a fine particle size range,
  • the oleic acid is mixed with the trichloroflurormethane at a temperature of 10°-15° C. and the micronised drug is mixed into the solution with a high shear mixer.
  • the suspension is metered into aluminium aerosol cans and suitable metering valves, delivering 85 mg of suspension are crimped onto the cans and the dichlorodifluoromethane is pressure filled into the cans through the valves.
  • the active ingredient is dissolved in the ethanol together with the oleic acid or surfactant if used.
  • the alcoholic solution is metered into suitable aerosol containers followed by the trichlorofluoromethane.
  • Suitable metering valves are crimped onto the containers and dichlorodifluoromethane is pressure filled into them through the valves.
  • LPS-lipopolysaccharide PAF-platalet activating factor
  • BALF-bronchoalveolar fluid PPE-plasma protein extravasation
  • PMN-guinea pig peritoneal neutrophil PAF-platalet activating factor
  • human lung fragments were sensitised by incubation overnight at 20° C. in serum from an allergic donor.
  • the lung fragments were then pre-incubated with varying concentrations (0.3-300 nM) of ⁇ 2 -adrenoreceptor agonists for 30 min. before being challenged with specific antigen.
  • the supernatants were assayed for mediator release, (leukotriene C 4 , D 4 , and E 4 ) by radio-immunoassay (Amersham, UK). Inhibition of mediator release was calculated as described by Butchers et al (1979) supra.
  • sensitised human lung fragments were pre-incubated with a single concentration of compound sufficient to cause just maximum inhibition of mediator release. The fragments were then washed and incubated in a large volume of Tyrode's solution at 37° C. Aliquots were removed at varying time intervals (0-20 h), challenged with antigen and mediator release measured as described above.
  • the racemate of Compound A (0.1-10 nM), the (R) enantiomer of Compound A (0.1-10 nM) and the (S) enantiomer of Compound A (0.1-10 nM) caused a concentration-dependent inhibition of mediator release (leukotriene C 4 /D 4 /E 4 ) from human lung fragments with IC 50 's of 0.5-1.5 nM, 0.1-1.0 nM and 5.0-10 nM, respectively.
  • Salbutamol in similar experiments has an IC 50 of 10-50 nM.
  • Guinea-pigs (Dunkin-Hartley, 200 g) were sensitized by two intraperitoneal injections of 10 ⁇ g ovalbumin two weeks apart (Sanjar et al, Br. J. Pharmacol., 99, 679-686, 1990).
  • the total numbers of leucocytes in the bronchoalveolar (BAL) fluid recovered was determined using a Medonic CA480 cell analyser. Numbers of eosinophils were calculated from differential cell counts carried out after staining in Leishmann's solution.
  • Data are expressed as means ⁇ s.e. mean of 4 animals/group.
  • guinea-pigs male Dunkin Hartley, 300-400 g
  • heparinised saline 10 U.ml -1
  • Animals were then exposed to an aerosol of histamine (0.5 mg.ml -1 ) generated by a Devilbiss nebuliser for 30 sec, followed by a further 30 sec exposure to the atmosphere in the chamber.
  • histamine 0.5 mg.ml -1
  • a blood sample was taken and the lungs lavaged twice with 10 ml heparinised (10 U.ml -1 ) phosphate-buffered saline at 37° C.
  • the radioactivity in both an aliquot of plasma and in a 5 ml sample of the pooled bronchoalveolar lavage fluid (BALF) was measured.
  • Plasma protein extravasation (PPE; ⁇ l plasma.ml -1 BALF) was calculated.
  • ⁇ 2 -adrenoreceptor agonists were administered by aerosol as described by Ball et al Br.J.Pharmac., 90 150P (1987), at timed intervals before histamine challenge.
  • the (R) enantiomer of Compound A inhibited histamine-induced PPE in a concentration-related manner, the highest doses causing complete inhibition (FIG. 2).
  • the concentration of the (R) enantiomer of Compound A required to reduce histamine-induced PPE by 50% (ED 50 ) was about 0.003 mg.ml -1 .
  • Guinea-pigs were anaesthesised with ketamine/xylazine i.m. followed by an intracardiac injection of iodinated human serum albumin.
  • Each guinea-pig received a series of intradermal injections (usually six) of sterile saline (50 ⁇ l) or ⁇ -adrenoreceptor agonist dissolved in sterile saline into the abdominal skin.
  • sterile saline 50 ⁇ l
  • ⁇ -adrenoreceptor agonist dissolved in sterile saline into the abdominal skin.
  • each animal received an intradermal injection of saline (50 ⁇ l) or bradykinin (10 -10 -10 -6 moles) in sterile saline into the same sites.
  • saline 50 ⁇ l
  • bradykinin 10 -10 -10 -6 moles
  • the iodinated albumin content of the plasma and skin biopsies was determined by scintillation counting. From these data, plasma protein extravasation, expressed as ⁇ l plasma per site, was calculated. All values for plasma protein extravasation quoted are corrected for that seen following an intradermal injection of saline.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention provides a new medical use for the dichloroaniline 4-amino-3,5-dichloro-(alpha)-(((6-(2-(2-pyridinyl)ethoxy)hexyl)amino)methyl)benzenemethanol and its enantiomers, and physiologically acceptable salts and solvates thereof in the treatment of inflammation, allergy and allergic reaction.

Description

This invention relates to a new medical use for the dichloroaniline compound 4-amino-3,5-dichloro-α-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzenemethanol, physiologically acceptable salts and solvates thereof and pharmaceutical compositions containing them which are disclosed in published UK Patent Specification No. 2187734A, in the treatment of inflammation, allergy, and allergic reaction.
Acute inflammation is the result of a number of processes including the activation of inflammatory cells and their accumulation in tissues; the local release of pro-inflammatory and chemotactic mediators; and vascular permeability changes which lead to plasma protein extravasation (PPE) and oedema formation.
One particular clinical condition with which inflammatory processes are associated is bronchial asthma. As reported by S. T. Holgate, Postgrad. Med. J., 64, 82-95 (1988), bronchial asthma is a multifactorial disease characterised by episodic bronchoconstriction, airway hyper-reactivity, inflammation and mucus abnormalities.
To date, bronchial asthma has been treated by combination therapy, using selective β2 -stimulants such as salbutamol to control bronchospasm and steroidal drugs such as beclomethasone dipropionate to control the inflammatory condition. β2 -adrenoreceptor agonists including salbutamol have been reported to exhibit inhibitory effects on inflammatory mediator release (see, for instance, P. R. Butchers et, al., Br. J. Pharmac., 71, 663-667 (1980) and P. H. Howarth et al., Am. Rev Resp. Dis., 132, 985-992 (1985)), however, β2 -adrenoreceptor agonists are not widely recognised as having significant clinical anti-inflammatory properties. Furthermore, such β2 -stimulants do not inhibit the so-called late asthmatic response which is classically observed some three to five hours after allergen exposure following recovery from the early asthmatic response. The late asthmatic response is not alleviated by treatment with conventional β2 -stimulants.
Published UK Patent Specification No. 2187734A discloses compounds which may be represented by the formula (I) ##STR1## wherein
X represents a bond or a C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene chain;
Y represents a bond or a C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is not more than 8;
Py represents a pyridinyl group optionally substituted by one or two substituents selected from halogen atoms, or hydroxy, C1-3 alkyl or C1-3 alkoxy groups; and
R1 and R2 each represents a hydrogen atom or C1-3 alkyl group with the proviso that the sum total of carbon atoms in R1 and R2 is not more than 4; and physiologically acceptable salts and solvates (e.g. hydrates) thereof.
Suitable physiologically acceptable salts of the compounds of general formula (I) include acid addition salts derived from inorganic and organic acids, such as hydrochlorides, hydrobromides, sulphates, phosphates, maleates, tartrates, citrates, benzoates, 4-methoxybenzoates, 2- or 4-hydroxybenzoates, 4-chlorobenzoates, benzenesulphonates, p-toluenesulphonates, methanesulphonates, naphthalenesulphonates, fumarates, succinates, lactates, glutarates, gluconates, tricarballylates, hydroxy-naphthalenecarboxylates e.g. 1-hydroxy-or 3-hydroxy-2-naphthalenecarboxylates, or oleates.
A preferred compound of formula (I) for use according to the present invention is 4-amino-3,5-dichloro-α-[[[6-[2-(2-pyridinyl) ethoxy]hexyl]amino]methyl]benzenemethanol, hereinafter referred to as "Compound A", which may be represented by the formula (Ia) ##STR2## and its physiologically acceptable salts and solvates.
Compound A is preferably administered in the form of its fumarate salt preferably, its z:1 fumarate salt.
The compounds disclosed in the aforementioned patent specification are described as selective β2 -adrenoreceptor agonists having a long duration of action which are particularly useful in the treatment of diseases associated with reversible airways obstruction, such as asthma and chronic bronchitis.
We have now found that contrary to the general findings for β2 -adrenoreceptor agonists, the compounds of formula (I) exhibit a significant anti-inflammatory activity in vivo over a prolonged period such that the compounds of formula (I) are effective in the treatment of the inflammatory component of bronchial asthma.
By virtue of its anti-inflammatory activity, Compound A or a physiologically acceptable salt or solvate thereof may be used in the treatment of a mammal, including man, suffering from pulmonary inflammation including alveolar inflammation and inflammation of the respiratory airways. In particular, Compound A or a physiologically acceptable salt or solvate thereof is useful in the treatment of inflammation associated with pulmonary diseases such as asthma and chronic bronchitis, emphysema, cystic fibrosis and adult respiratory distress syndrome (ARDS).
Compound A or a physiologically acceptable salt or solvate thereof may also be used in the treatment of a mammal, including man, suffering from pulmonary inflammation associated with the late asthmatic response.
Additionally, Compound A or a physiologically acceptable salt or solvate thereof may be used in the treatment of a mammal, including man, suffering from an allergy or allergic reaction such as allergic rhinitis, contact dermatitis, allergic conjunctivitis and the like or an inflammatory condition such as episcleritis, tendinitis, rheumatoid opondylitis, osteoarthritis, gouty arthritis and other arthritic conditions.
Compound A or a physiologically acceptable salt or solvate thereof is particularly useful in the treatment of inflammatory and allergic skin diseases such as, for example, urticaria, psoriasis, eczema and atopic dermatitis.
Compound A or a physiologically acceptable salt or solvate thereof may also be used in the treatment of a mammal, including man, suffering from inflammation of the gastrointestinal tract. Such conditions may be for example, ulcerative colitis, Crohn's disease, damage caused by non-steroidal drugs, and inflammatory bowel disease.
According to one aspect of the invention we therefore provide a therapeutic agent comprising as active ingredient Compound A or a physiologically acceptable salt or solvate thereof for use in treating, relieving or preventing the effects of inflammation, allergy, or allergic reaction.
In an alternative or further aspect the invention provides a method of treatment of a mammal, including man, suffering from or susceptible to the effects of inflammation, allergy or allergic reaction which comprises administering an effective amount of Compound A or a physiologically acceptable salt or solvate thereof. It will be appreciated that whilst Compound A will primarily be of use in the alleviation of established symptoms, prophylaxis is not excluded.
In a further aspect, the invention provides Compound A or a physiologically acceptable salt or solvate thereof for use in the manufacture of a medicament for treating relieving or preventing the effects of inflammation, allergy, or allergic reaction.
A particularly preferred compound for use in accordance with the present invention is the (R) enantiomer of Compound A or a physiologically acceptable salt or solvate thereof.
Preparation of the (R) and (S) enantiomers of Compound A is described in European Patent Specification No. 0460924, the contents of which are incorporated herein by way of reference.
The anti-inflammatory activity of Compound A in the lung was assessed by investigating the effect of the drug on inflammatory mediator release in human lung tissues in vitro, and on inflammatory cell infiltration and accumulation, and vascular permeability and plasma protein extravasation in the airway lumen of the guinea-pig in vivo (see Example 1, below).
The anti-inflammatory activity of the Compound A in the skin was assessed by investigating the effect of the drug on plasma protein extravasation (PPE) as a measure of vascular permeability (see Example 2, below).
Thus, in an alternative or further aspect the invention provides Compound A or a physiologically acceptable salt or solvate thereof for use in treating, relieving or preventing a disease involving inflammatory cell accumulation in the lungs.
Additionally the invention provides Compound A or a physiologically acceptable salt or solvate thereof for use in treating, relieving or preventing a disease involving increased vascular permeability and plasma protein extravasation in the lungs.
The invention further provides Compound A or a physiologically acceptable salt or solvate thereof for use in treating, relieving or preventing a disease involving granulocyte accumulation in the skin.
The invention still further provides Compound A or a physiologically acceptable salt or solvate thereof for use in treating, relieving or preventing a disease involving increased vascular permeability in the skin.
As used herein, the term "increased vascular permeability" is intended to refer to elevated levels of vascular permeability with respect to those generally observed in a healthy individual.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a comparison of the inhibition by the (R)-enantiomer of Compound A and salbutamol of leukotriene release from human lung tissue fragments in vitro.
FIG. 2 shows the inhibition by the (R)-enantiomer of Compound A of histamine-induced plasma protein extravasation (PPE) in guinea pig lung in vivo.
FIG. 3 shows the duration of inhibition by the (R)-enantiomer of Compound A of histamine-induced plasma protein extravasation (PPE) in guinea pig lung in vivo.
FIG. 4 shows the duration of inhibition by salbutamol of histamine-induced plasma protein extravasation (PPE) in guinea pig lung in vivo (for comparison with FIG. 3).
FIG. 5 shows the inhibition by the (R)-enantiomer of Compound A of bradykinin-induced plasma protein extravasation (PPE) in guinea pig skin.
FIG. 6 shows the inhibition by the (S)-enantiomer of Compound A of bradykinin-induced plasma protein extravasation (PPE) in guinea pig skin.
While it is possible for Compound A to be administered alone as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation. Formulations of Compound A for use according to the invention, both for veterinary and for human medical use, comprise the active compound together with one or more pharmaceutically acceptable carriers and optionally any other therapeutic ingredients. The carriers must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The other therapeutic ingredients may include analgesics, such as aspirin or codeine, anti-pyretics, or other anti-inflammatories.
Compound A for use according to the invention may be formulated in a conventional manner for administration by any convenient route, for example for administration by inhalation or insufflation, or for oral, buccal, parenteral, topical (including nasal) or rectal administration.
For administration by inhalation the compound for use according to the invention is conveniently delivered in the form of an aerosol spray presentation from pressurised packs, with the use of a suitable propellants such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas, or from a nebuliser. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.
Alternatively, for administration by inhalation or insufflation, Compound A may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such a lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges of e.g. gelatin, or blister packs from which the powder may be administered with the aid of an inhaler or insufflator.
For oral administration, the pharmaceutical composition may take the form of, for example, tablets, capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.
For buccal administration the composition may take the form of tablets, drops or lozenges formulated in a conventional a manner.
Compound A may be formulated for parenteral administration. Formulations for injections may be presented in unit form in ampoules, or multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g sterile pyrogen-free water, before use.
For topical administration the pharmaceutical composition may take the form of ointments, lotions or creams formulated in a conventional manner, with for example an aqueous oily base, generally with the addition of suitable thickening agents and or solvents. For nasal application, the composition may take the form of a spray, formulated for example as an aqueous solution or suspension or as an aerosol with the use of a suitable propellant.
Compound A may also be formulated in rectal compositions such as suppositories or retention enemas, e.g containing conventional suppository bases such as cocoa butter or other glycerides.
Where pharmaceutical compositions are described above for oral, buccal, rectal or topical administration, these may be presented in a conventional manner associated with controlled release forms.
A proposed daily dosage of active compound for the treatment of man is 0.0005 mg to 100 mg, which may be conveniently administered in one or two doses. The precise dose employed will of course depend on the age and condition of the patient and on the route of administration. Thus a suitable dose for administration by inhalation is 0.0005 mg to 10 mg, for oral administation is 0.02 mg to 100 mg, and for parenteral administration is 0.001 mg to 2 mg.
The following are examples of suitable formulations for use in invention. The term "active ingredient" is used herein to represent Compound A.
Tablets
These may be prepared by the normal methods such as wet granulation or direct compression.
______________________________________                                    
A. Direct Compression                                                     
                   mg/tablet                                              
______________________________________                                    
Active ingredient     2.0                                                 
Microcrystalline Cellulose USP                                            
                     196.5                                                
Magnesium Stearate BP                                                     
                      1.5                                                 
Compression weight   200.0                                                
______________________________________
The active ingredient is sieved through a suitable sieve, blended with the excipients and compressed using 7 mm diameter punches.
Tablets of other strengths may be prepared by altering the ratio of active ingredient to microcrystalline cellulose or the compression weight and using punches to suit.
______________________________________                                    
B. Wet Granulation                                                        
                   mg/tablet                                              
______________________________________                                    
Active ingredient     2.0                                                 
Lactose BP           151.5                                                
Starch BP             30.0                                                
Pregelatinised Maize Starch BP                                            
                      15.0                                                
Magnesium Stearate BP                                                     
                      1.5                                                 
Compression weight   200.0                                                
______________________________________
The active ingredient is sieved through a suitable sieve and blended with lactose, starch and pregelatinised maize starch. Suitable volumes of purified water are added and the powders are granulated. After drying, the granules are then compressed into tablets using 7 mm diameter punches. Tablets of other strengths may be prepared by altering the ratio of active ingredient to lactose or the compression weight and using punches to suit.
Injection for intravenous Administration
______________________________________                                    
                  mg/ml                                                   
______________________________________                                    
Active ingredient   0.5       mg                                          
Sodium Chloride BP  as required                                           
Water for injection BP to                                                 
                    1.0       ml                                          
______________________________________
Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted, using acid or alkali, to that of optimum stability and/or facilitate solution of the active ingredient. Alternatively suitable buffer salts may be used.
The solution is prepared, clarified and filled into appropriate size ampoules sealed by fusion of the glass. The injection is sterilised by heating in an autoclave using one of the acceptable cycles. Alternatively the solution may be sterilised by filtration and filled into sterile ampoules under acceptable conditions. The solution may be packed under an inert atmosphere of nitrogen or other suitable gas.
Metered Dose Pressurised Aerosol
______________________________________                                    
A. Suspension Aerosol                                                     
              mg/metered dose                                             
                          per can                                         
______________________________________                                    
Active ingredient micronised                                              
                 0.100        26.40   mg                                  
Oleic Acid BP    0.010        2.64    mg                                  
Trichlorofluoromethane BP                                                 
                23.64         5.67    g                                   
Dichlorodifluoromethane BP                                                
                51.25         14.70   g                                   
______________________________________
The active ingredient is micronised in a fluid energy mill to a fine particle size range, The oleic acid is mixed with the trichloroflurormethane at a temperature of 10°-15° C. and the micronised drug is mixed into the solution with a high shear mixer. The suspension is metered into aluminium aerosol cans and suitable metering valves, delivering 85 mg of suspension are crimped onto the cans and the dichlorodifluoromethane is pressure filled into the cans through the valves.
______________________________________                                    
B. Solution Aerosol                                                       
              mg/metered dose                                             
                          per can                                         
______________________________________                                    
Active ingredient                                                         
                 0.100        24.0    mg                                  
Ethanol BP       7.500        1.80    g                                   
Trichlorofluoromethane BP                                                 
                18.875        4.53    g                                   
Dichlorodifluoromethane BP                                                
                48.525        11.65   g                                   
______________________________________                                    
 Oleic acid BP, or a suitable surfactant e.g. Span 85 (sorbitan trioleate)
 may also be included.
The active ingredient is dissolved in the ethanol together with the oleic acid or surfactant if used. the alcoholic solution is metered into suitable aerosol containers followed by the trichlorofluoromethane. Suitable metering valves are crimped onto the containers and dichlorodifluoromethane is pressure filled into them through the valves.
The following examples illustrate the studies demonstrating the potent and long-acting anti-inflammatory activity effect of Compound A in the lung and in the skin.
The following abbreviation are used in: LPS-lipopolysaccharide; PAF-platalet activating factor; BALF-bronchoalveolar fluid; PPE-plasma protein extravasation; PMN-guinea pig peritoneal neutrophil.
EXAMPLE 1 ANTI-INFLAMMATORY ACTIVITY IN THE LUNG
(i) Inflammatory Mediator Release
The effect of β2 -adrenoreceptor agonists on inflammatory mediator release was evaluated using the method of Butchers et al Br.J.Pharmac., 67, 23-32 (1979).
Briefly, human lung fragments were sensitised by incubation overnight at 20° C. in serum from an allergic donor. The lung fragments were then pre-incubated with varying concentrations (0.3-300 nM) of β2 -adrenoreceptor agonists for 30 min. before being challenged with specific antigen. The supernatants were assayed for mediator release, (leukotriene C4, D4, and E4) by radio-immunoassay (Amersham, UK). Inhibition of mediator release was calculated as described by Butchers et al (1979) supra.
To compare the duration of action of β2 -agonists, sensitised human lung fragments were pre-incubated with a single concentration of compound sufficient to cause just maximum inhibition of mediator release. The fragments were then washed and incubated in a large volume of Tyrode's solution at 37° C. Aliquots were removed at varying time intervals (0-20 h), challenged with antigen and mediator release measured as described above.
The racemate of Compound A (0.1-10 nM), the (R) enantiomer of Compound A (0.1-10 nM) and the (S) enantiomer of Compound A (0.1-10 nM) caused a concentration-dependent inhibition of mediator release (leukotriene C4 /D4 /E4) from human lung fragments with IC50 's of 0.5-1.5 nM, 0.1-1.0 nM and 5.0-10 nM, respectively. Salbutamol in similar experiments has an IC50 of 10-50 nM.
Inhibition of leukotriene release by Compound A (40 nM) was sustained, significant inhibitory activity still being observed after 20 h (FIG. 1). In contrast, the effect of an equipotent concentration of salbutamol (200 nM) was poorly maintained, with loss of inhibitory activity within 2-4 h (FIG. 1).
(ii) Inflammatory cell Accumulation
Guinea-pigs (Dunkin-Hartley, 200 g) were sensitized by two intraperitoneal injections of 10 μg ovalbumin two weeks apart (Sanjar et al, Br. J. Pharmacol., 99, 679-686, 1990).
Two weeks later the animals were exposed to aerosols derived from solutions of the (R) enantiomer of Compound A (12 mM) or vehicle for 15 min. prior to antigen challenge. The antigen challenge was an aerosol of 0.005% ovalbumin in phosphate-buffered saline given for 30 min. The animals were predosed with mepyramine (1 mg/kg i.p.) to prevent terminal bronchoconstriction. The animals were killed 24 hr later and bronchial lavage performed.
The total numbers of leucocytes in the bronchoalveolar (BAL) fluid recovered was determined using a Medonic CA480 cell analyser. Numbers of eosinophils were calculated from differential cell counts carried out after staining in Leishmann's solution.
Although the lungs of unchallenged animals contain eosinophils, antigen challenge caused an approximate 4-fold increase in the number of eosinophils recovered in BAL fluid (table 1). Pretreatment of the animals with the (R) enantiomer of Compound A inhibited this response to antigen by about 60%.
              TABLE 1                                                     
______________________________________                                    
EOSINOPHILS × 10.sup.5 /ml BAL FLUID                                
______________________________________                                    
Unchallenged         1.69 ± 0.47                                       
Challenged           7.22 ± 1.42                                       
Challenged +(R) enantiomer of                                             
                     3.85 ± 1.80                                       
Compound A (12 mM)                                                        
______________________________________
Data are expressed as means ± s.e. mean of 4 animals/group.
(iii) Vascular Permeability and Plasma Protein Extravasation
The method of evaluating the effects of β2 -adrenoreceptor agonists on vascular permeability and plasma protein extravasation was adapted from the technique of Erjefalt et al Acta.Physiol.Scand., 128, 653-654 (1986).
Briefly, guinea-pigs (male Dunkin Hartley, 300-400 g) were given an intracardiac injection of iodinated human serum albumin (0.5 μCi) in heparinised saline (10 U.ml-1). Animals were then exposed to an aerosol of histamine (0.5 mg.ml-1) generated by a Devilbiss nebuliser for 30 sec, followed by a further 30 sec exposure to the atmosphere in the chamber. Thirty minutes after histamine challenge, a blood sample was taken and the lungs lavaged twice with 10 ml heparinised (10 U.ml-1) phosphate-buffered saline at 37° C. The radioactivity in both an aliquot of plasma and in a 5 ml sample of the pooled bronchoalveolar lavage fluid (BALF) was measured. Plasma protein extravasation (PPE; μl plasma.ml-1 BALF) was calculated. β2 -adrenoreceptor agonists were administered by aerosol as described by Ball et al Br.J.Pharmac., 90 150P (1987), at timed intervals before histamine challenge.
The (R) enantiomer of Compound A (nebuliser concentration: 0.001-1 mg.ml-1) inhibited histamine-induced PPE in a concentration-related manner, the highest doses causing complete inhibition (FIG. 2). The concentration of the (R) enantiomer of Compound A required to reduce histamine-induced PPE by 50% (ED50) was about 0.003 mg.ml-1.
Inhibition of histamine induced PPE by the inhaled (R) enantiomer of Compound A was long-lasting, still being evident 4 hours after administration (FIG. 3). In contrast, at equi-effective doses, salbutamol had a shorter duration of action, with substantial loss of activity after 2 hours (FIG. 4).
EXAMPLE 2 ANTI-INFLAMMATORY ACTIVITY IN THE SKIN
(i) Bradykinin-Induced Increases in Vascular Permeability
Guinea-pigs were anaesthesised with ketamine/xylazine i.m. followed by an intracardiac injection of iodinated human serum albumin. Each guinea-pig received a series of intradermal injections (usually six) of sterile saline (50 μl) or β-adrenoreceptor agonist dissolved in sterile saline into the abdominal skin. Fifteen minutes later, each animal received an intradermal injection of saline (50 μl) or bradykinin (10-10 -10-6 moles) in sterile saline into the same sites. Thus in each guinea-pig six sites were injected with either sterile saline or bradykinin following pretreatment with either sterile saline or β-adrenoreceptor agonist.
Thirty minutes later all guinea-pigs were killed with an overdose of sodium pentobarbitone, a plasma sample prepared and the skin sites removed with a hollow punch.
The iodinated albumin content of the plasma and skin biopsies was determined by scintillation counting. From these data, plasma protein extravasation, expressed as μl plasma per site, was calculated. All values for plasma protein extravasation quoted are corrected for that seen following an intradermal injection of saline.
Intradermal injection of the (R) enantiomer of Compound A (10-10 -10-8 moles/site) did not cause plasma protein extravasation.
Intradermal administration of the (R) enantiomer of Compound A (10-9 and 10-8 moles/site) 15 min prior to bradykinin markedly reduced plasma protein extravasation induced by a range of doses of bradykinin (FIG. 5).
The (S) enantiomer of Compound A (10-9 and 10-8 moles/site) also inhibited bradykinin-induced PPE (FIG. 6).

Claims (7)

We claim:
1. A method of treatment of a mammal, including man, suffering from the effects of pulmonary inflammation associated with the late asthmatic response which comprises administering an effective amount of the compound of formula (1a) ##STR3## or a physiologically acceptable salt or solvate thereof.
2. A method of treatment according to claim 1 which comprises administering an effective amount of the (R)-enantiomer of the compound of formula (1a) or a physiologically acceptable salt or solvent thereof.
3. A method of treatment according to claim 1 wherein the compound of formula (1a) is in the form of its 2:1 fumarate salt.
4. A method of treatment according to claim 2 wherein the compound of formula (1a) is in the form of its 2:1 fumarate salt.
5. A method of treatment according to claim 1 wherein the compound of formula (1a) or a physiologically acceptable salt or solvate thereof is administered by inhalation or by insufflation.
6. A method of treatment according to claim 3 wherein the compound of formula (1a) or a physiologically acceptable salt or solvate thereof is administered by inhalation or by insufflation.
7. A method of treatment according to claim 4 wherein the compound of formula (1a) or a physiologically acceptable salt or solvate thereof is administered by inhalation or by insufflation.
US07/846,011 1991-03-05 1992-03-04 Compounds for the treatment of inflammation and allergy Expired - Fee Related US5283268A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919104650A GB9104650D0 (en) 1991-03-05 1991-03-05 Medicaments
GB9104650 1991-03-05

Publications (1)

Publication Number Publication Date
US5283268A true US5283268A (en) 1994-02-01

Family

ID=10691036

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/846,011 Expired - Fee Related US5283268A (en) 1991-03-05 1992-03-04 Compounds for the treatment of inflammation and allergy

Country Status (4)

Country Link
US (1) US5283268A (en)
EP (1) EP0502470A3 (en)
JP (1) JPH0687744A (en)
GB (1) GB9104650D0 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5881720A (en) * 1997-04-29 1999-03-16 The Procter & Gamble Company Method of delivering halotherapy
US20040235811A1 (en) * 2002-10-08 2004-11-25 Sepracor Inc. Fatty acid modified forms of glucocorticoids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187734A (en) * 1986-02-12 1987-09-16 Glaxo Group Ltd Dichloroaniline derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1005612A5 (en) * 1990-06-05 1993-11-23 Glaxo Group Ltd Derivative dichloroaniline.
NZ238749A (en) * 1990-06-28 1993-07-27 Glaxo Inc Aerosol inhalation drug formulations with 1,1,1,2-tetrafluoroethane as propellant and a perfluorinated surfactant
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187734A (en) * 1986-02-12 1987-09-16 Glaxo Group Ltd Dichloroaniline derivatives
US4937251A (en) * 1986-02-12 1990-06-26 Glaxo Group Limited Dichloroaniline compounds useful for method of therapy or prophylaxis of a disease associated with reversible airway obstruction

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Anonymous, Doctor, 36, Nov. 19, 1989. *
Anonymous, Doctor, 73, Feb. 23, 1989. *
Anonymous, Hospital Doctor, C9(10), 35, 1989. *
Anonymous, Mims Magazine, 16, Mar. 15, 1989. *
Anonymous, Pharm. J., 244(6579), 414, Apr. 7, 1990. *
Baker et al., Am. Rev. Resp. Dis., 141 (4 pt 2), May 20 24, 1990. *
Baker et al., Am. Rev. Resp. Dis., 141 (4 pt 2), May 20-24, 1990.
Butchers et al., Br. J. Pharmac., 71, 663 667, 1980. *
Butchers et al., Br. J. Pharmac., 71, 663-667, 1980.
Butchers et al., Br. J. Pharmacol., 92, 745P, 1987. *
Deuchar, Pulse, 14, Oct. 1986. *
Howarth et al., Am. Rev. Resp. Dis., 132, 986 992, 1985. *
Howarth et al., Am. Rev. Resp. Dis., 132, 986-992, 1985.
Johnson et al., Eur. Resp. J., 2(suppl. 8), 676s, abst. no. 201, 1989. *
Johnson, Eur. Resp. J., 2(suppl. 8), 755s, abst. no. 561a, 1989. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5881720A (en) * 1997-04-29 1999-03-16 The Procter & Gamble Company Method of delivering halotherapy
US20040235811A1 (en) * 2002-10-08 2004-11-25 Sepracor Inc. Fatty acid modified forms of glucocorticoids
US20070060555A1 (en) * 2002-10-08 2007-03-15 Sepracor Inc. Fatty acid modified forms of glucocorticoids
US7390796B2 (en) * 2002-10-08 2008-06-24 Sepracor Inc. Fatty acid modified forms of glucocorticoids
US20080221072A1 (en) * 2002-10-08 2008-09-11 Sepracor Inc. Fatty Acid Modified Forms of Glucocorticoids

Also Published As

Publication number Publication date
EP0502470A2 (en) 1992-09-09
GB9104650D0 (en) 1991-04-17
JPH0687744A (en) 1994-03-29
EP0502470A3 (en) 1993-01-27

Similar Documents

Publication Publication Date Title
US5290815A (en) Treatment of inflammation and allergy
EP0416925A2 (en) Use of 4-hydroxy-alpha 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol or its salts in the treatment of allergy and inflammation
EP2968312B1 (en) Drug combination
EP1603565B1 (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
Akerele et al. Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics
CA2372443C (en) Local administration of anti-malarial agents for the treatment of inflammatory diseases
US5578632A (en) Medicaments for the treatment of gastrointestinal dysfunction
TW200529855A (en) Use of substituted pteridines for the treatment of respiratory diseases
US4452800A (en) Salts of 3(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one and their use in treating chronic obstructive lung diseases
CA2519679C (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
EP1092431B1 (en) Lasofoxifene compositions
US5283268A (en) Compounds for the treatment of inflammation and allergy
WO2001032166A1 (en) NEW COMBINATION COMPRISING A β2-ADRENORECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST
EP1610788A1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
AU763979B2 (en) Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
CA1273875A (en) Antiinflammatory compositions and methods
NZ239201A (en) Pharmaceutical compositions comprising a paf antagonist and an ltd4
US5240954A (en) Medicaments
JPS62135424A (en) Prazosin-pirbuterol composition for bronchodialation
EP0817631A2 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
US7932276B2 (en) Agent for curing chronic obstructive pulmonary disease
WO1998034615A1 (en) Pharmaceutical composition for treatment of synaptic dysfunction comprising an oxime
JPS62294614A (en) Novel pharmaceutical composition comprising benzo[c][1,6]naphthyridine derivative
US4271191A (en) Method of treating hyperuricemia and gout
AU2001264806A1 (en) Stable liquid and solid formulations

Legal Events

Date Code Title Description
AS Assignment

Owner name: GLAXO GROUP LIMITED, A BRITISH COMPANY, GREAT BRIT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:JOHNSON, MALCOLM;WHELAN, CLIFFORD J.;REEL/FRAME:006089/0862

Effective date: 19920408

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19980204

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362